Finance

Beta
Roʻyxatlar
Aksiyalar sektorlari
Belgilar
Belgilar
Narxi
Oʻzgartirishlar
Dinamika (%)
Trend
Avvalgi yopilish narxi
Ochish
Yuqori
Past
Hajmi
Bozor kapitali
SIXB
Materials
SIXB
Materials
SIXB
-1,13%
1 088,13
-12,44
-1,13%
1 100,571 098,941 103,801 084,24
SIXC
Communications
SIXC
Communications
SIXC
-0,29%
603,39
-1,76
-0,29%
605,15605,15606,69602,76
SIXE
Energy
SIXE
Energy
SIXE
+1,82%
1 216,94
+21,75
+1,82%
1 195,191 204,711 217,721 204,71
SIXI
Industrials
SIXI
Industrials
SIXI
-1,30%
1 717,25
-22,66
-1,30%
1 739,911 734,501 734,501 710,67
SIXM
Financials
SIXM
Financials
SIXM
+0,53%
641,95
+3,39
+0,53%
638,56640,21645,32639,66
SIXR
Staples
SIXR
Staples
SIXR
+1,26%
842,02
+10,45
+1,26%
831,57840,48843,98834,54
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,64%
214,73
+1,37
+0,64%
213,36213,36215,54212,77
SIXT
Technology
SIXT
Technology
SIXT
-2,27%
3 160,78
-73,40
-2,27%
3 234,183 171,863 195,363 145,46
SIXU
Utilities
SIXU
Utilities
SIXU
+0,42%
939,56
+3,91
+0,42%
935,65937,31941,44933,16
SIXV
Health care
SIXV
Health care
SIXV
+0,59%
1 457,80
+8,54
+0,59%
1 449,261 454,771 462,651 452,87
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,49%
2 370,89
-11,56
-0,49%
2 382,452 371,192 380,452 364,46
Q1 2026 daromadi • 2 kundan keyin
Tafsilotlar
AMG:ETR
Amgen
296,20 €
+1,01%
(+2,95) 1K
28-apr, 15:33:52 (GMT+2)  ·   EUR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
AMG tikeri uchun statistika yaratilmoqda...
Ochish
290,10 €
Yuqori
296,20 €
Past
290,05 €
Bozor kapitali
185,29 mlrd
Oʻrtacha hajm
306,00
Hajmi
216,00
52 haftalik eng yuqori
333,00 €
52 haftalik eng past
230,00 €
Xodimlar soni
32 ming
Yangiliklar
Internetdagi manbalardan
Profil
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Amgen haqida
CEORobert A. Bradway
Xodimlar soni31,5 ming
Asos solingan8-apr, 1980
Bosh ofislarTauzand-Oks, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytamgen.com
Keyingi hisobot: 2 kundan keyin
Pay, 30-apr, 16:30
Moliya davri
Ch.1 2026
Normallashtirilgan EPS / Taxminiy
-/ (4,77 taxm.)USD
Daromad / Taxminan
-/ (8,57 mlrd taxm.)USD
Q1 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha: kelgusi tushumlarOxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – USD
mar, 2025
iyn, 2025
sen, 2025
dek, 2025
Daromad
8,15 mlrd
9,18 mlrd
9,56 mlrd
9,87 mlrd
Sotilgan mahsulotning tannarxi
2,60 mlrd
2,67 mlrd
2,74 mlrd
2,68 mlrd
Daromad narxi
2,60 mlrd
2,67 mlrd
2,74 mlrd
2,68 mlrd
Tadqiqot va ishlanmalarga xarajatlar
1,49 mlrd
1,74 mlrd
1,90 mlrd
2,14 mlrd
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
1,69 mlrd
1,69 mlrd
1,72 mlrd
1,95 mlrd
Operatsion xarajatlar
3,20 mlrd
3,50 mlrd
3,55 mlrd
4,18 mlrd
Jami operatsion xarajatlar
5,81 mlrd
6,18 mlrd
6,29 mlrd
6,85 mlrd
Operatsion daromad
2,34 mlrd
3,00 mlrd
3,26 mlrd
3,01 mlrd
Boshqa nooperatsion daromad
-36,00 mln
-113,00 mln
181,00 mln
143,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
1,97 mlrd
1,57 mlrd
3,92 mlrd
1,51 mlrd
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
1,66 mlrd
2,37 mlrd
2,72 mlrd
2,51 mlrd
Daromad soligʻi boʻyicha xarajat
243,00 mln
136,00 mln
705,00 mln
181,00 mln
Amaldagi soliq stavkasi
12,32%
8,67%
17,98%
11,96%
Boshqa operatsion xarajatlar
30,00 mln
68,00 mln
-71,00 mln
82,00 mln
Sof foyda
1,73 mlrd
1,43 mlrd
3,22 mlrd
1,33 mlrd
Sof foyda marjasi
21,23%
15,60%
33,65%
13,51%
Har bir aksiya foydasi
4,90
6,02
5,64
5,29
Foizlar va investitsiyalardan olingan daromadlar
-
-
-
408,00 mln
Foizlarni toʻlash xarajatlari
-723,00 mln
-694,00 mln
-685,00 mln
-1,06 mlrd
Foizlarni toʻlash boʻyicha sof xarajatlar
-723,00 mln
-694,00 mln
-685,00 mln
-653,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
3,73 mlrd
4,34 mlrd
4,57 mlrd
4,02 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil

Tahlil

Vazifalarim
Hali vazifa yaratmagansiz
Vazifalaringiz shu yerda chiqadi. Vazifalarni rejalashtiring va Google Finance xizmatidan foydalaning.
Andozalar
Kuzatuv roʻyxati brifingi
Kuzatuv roʻyxatining kunlik bozor oldidan tahlili
Kelgusi tushumlar
Hafta ichida kelgusi tushum hisobotlari
Anomal volatillik va hajm
Bugun erta ogohlantirish: volatillik va hajm
AI kontentda xatolar boʻlishi mumkin. Batafsil